{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T10:36:25Z","timestamp":1763202985201,"version":"3.40.4"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.trim.2025.102228","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T08:20:55Z","timestamp":1744186855000},"page":"102228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Allogenic stem cell transplantation response for relapsed or refractory Hodgkin lymphoma patients: An experience in Iran"],"prefix":"10.1016","volume":"90","author":[{"given":"Amineh","family":"Salem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahshid","family":"Mehdizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayeh","family":"Parkhideh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.trim.2025.102228_bb0005","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.trim.2025.102228_bb0010","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.trim.2025.102228_bb0015","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3816\/CLM.2009.n.042","article-title":"Hodgkin lymphoma: an update on its biology with new insights into classification","volume":"9","author":"Mani","year":"2009","journal-title":"Clin. Lymphoma Myeloma"},{"issue":"24","key":"10.1016\/j.trim.2025.102228_bb0020","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.trim.2025.102228_bb0025","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.2003.12.086","article-title":"Randomized comparison of ABVD and MOPP\/ABV hybrid for the treatment of advanced Hodgkin\u2019s disease: report of an intergroup trial","volume":"21","author":"Duggan","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.trim.2025.102228_bb0030","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin\u2019s lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.trim.2025.102228_bb0035","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1093\/annonc\/mdu387","article-title":"Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"25","author":"Gerrie","year":"2004","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.trim.2025.102228_bb0040","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.trim.2025.102228_bb0045","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood.V124.21.290.290","article-title":"PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013)","volume":"124","author":"Moskowitz","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.trim.2025.102228_bb0050","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3324\/haematol.2011.045757","volume":"97","author":"Sureda","year":"2012","journal-title":"Haematologica"},{"issue":"18","key":"10.1016\/j.trim.2025.102228_bb0055","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood-2009-12-253856","article-title":"Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability","volume":"115","author":"Sarina","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.trim.2025.102228_bb0060","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/10428194.2018.1459607","article-title":"Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free\/relapse-free survival","volume":"60","author":"Spina","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.trim.2025.102228_bb0065","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clml.2017.11.003","article-title":"How to approach a Hodgkin lymphoma patient with relapse after autologous SCT: allogeneic SCT","volume":"18","author":"Mei","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.trim.2025.102228_bb0070","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.15152","article-title":"Bloor a Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT lymphoma working party","volume":"181","author":"Bazarbachi","year":"2018","journal-title":"Brit. J. Haematol."},{"issue":"7","key":"10.1016\/j.trim.2025.102228_bb0075","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/bloodadvances.2017011122","article-title":"Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?","volume":"2","author":"Peggs","year":"2018","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.trim.2025.102228_bb0080","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/bjh.15639","article-title":"The role of transplantation in Hodgkin lymphoma","volume":"184","author":"Broccoli","year":"2019","journal-title":"Brit. J. Haematol."},{"issue":"5","key":"10.1016\/j.trim.2025.102228_bb0085","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PPO.0000000000000330","article-title":"Treatment-resistant Hodgkin lymphoma: defining the role of autologous transplantation","volume":"24","author":"Blum","year":"2018","journal-title":"Cancer J."},{"issue":"1","key":"10.1016\/j.trim.2025.102228_bb0090","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41409-019-0640-z","article-title":"Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment","volume":"55","author":"Rivas","year":"2020","journal-title":"Bone Marrow Transplant."},{"issue":"7","key":"10.1016\/j.trim.2025.102228_bb0095","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00277-019-03714-x","article-title":"Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin's lymphoma","volume":"98","author":"Jeon","year":"2019","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/j.trim.2025.102228_bb0100","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/gm240","article-title":"Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances","volume":"3","author":"Derenzini","year":"2011","journal-title":"Genome Med."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327425000565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327425000565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T02:27:55Z","timestamp":1746239275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327425000565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":20,"alternative-id":["S0966327425000565"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2025.102228","relation":{},"ISSN":["0966-3274"],"issn-type":[{"type":"print","value":"0966-3274"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogenic stem cell transplantation response for relapsed or refractory Hodgkin lymphoma patients: An experience in Iran","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2025.102228","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102228"}}